Neovasc — Investor Presentation (April 2013)
19 slides from Neovasc's investor presentation, April 2013
Slide 1: Neovasc Inc.
Neovasc Inc. TSXV: NVC Alexei Marko, CEO Chris Clark, CFO April 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo
Slide 3: Neovasc in Summary
Neovasc in Summary A Canadian small cap medical device company with existing revenues & two development products: Stage Product Growing Revenues Implantable biological tissue & services for transcatheter heart valves & other applications Late Stage Neovasc Reducer™ for treatment of refractory angina
Slide 4: Reducer Product
Reducer Product Treats Refractory Angina • Angina – Constant and severs heart pain caused by inadequate blood flow to heart muscle • Refractory – Angina that cannot be managed through conventional drug, catheter or surgical therapy • Large & growing population of untreatable patients – Improved card
Slide 5: Reducer Method of Action
Reducer Method of Action Reducer modulates outflow of blood from coronary veins, increasing blood flow to ischemic areas Blood flow takes path of Venous back pressure least resistance causes more uniform • Majority of blood flows distribution of blood around ischemic flow through heart areas muscle
Slide 6: Reducer Procedure
Reducer Procedure • Based on 1950’s surgical Beck Procedure • Reported excellent results but is no longer performed due to invasiveness • Reducer achieves same narrowing using modern non-surgical catheter- based techniques • Reducer procedure takes 20 minutes; patient discharged within 24 hours • Sa
Slide 7: Reducer Clinical Results
Reducer Clinical Results Compelling clinical data from 1st human trial (15 patients, 3 centers) • 6-month data published in May 2007 JACC demonstrated safety & significant improvement of angina symptoms • 3-year follow-up data confirms excellent long-term safety & treatment durability (presented at
Slide 8: Reducer COSIRA Trial
Reducer COSIRA Trial COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 110-124 patients • Randomized 1:1 to blinded treatment & sham control arms • Primary endpoint: Efficacy @ 6-months • Sites in Belgium, C
Slide 9: Reducer Timeline & Market Opportunity
Reducer Timeline & Market Opportunity Europe • CE mark received November 2011 • Complete COSIRA enrollment in Apr/May 2013 • Collect additional clinical data through registries initiated in Europe & Israel • Launch with distribution partner(s) following completion of COSIRA United States • FDA IDE t
Slide 10: Biological Tissue and Services
Biological Tissue and Services Neovasc is a turnkey solution for industry partners developing medical devices that incorporate pericardial tissue Tissue • Proprietary process creates implantable, biocompatible tissue from animal pericardium that retains strength & physical characteristics of natural
Slide 11: Transcatheter Heart Valve Applications
Transcatheter Heart Valve Applications Neovasc is the leading independent supplier of biological leaflet material & related services to companies developing transcatheter heart valves • 2011 sales of 1st generation transcatheter aortic valves $600M • 2012 sales estimated $900M • Next generation devi
Slide 12: Tiara Mitral Valve Replacement
Tiara Mitral Valve Replacement • Neovasc is developing Tiara, a novel transcatheter device for the treatment of mitral regurgitation (MR) • MR is serious & widespread condition that can cause significant disability or death • Significant portion of those with MR are non-surgical candidates • Tiara i
Slide 13: Tiara Key Features
Tiara Key Features • Design is specific to mitral anatomy & matches natural shape of mitral annulus • Resists high dislodgment forces during systole • Exerts minimal radial force on mitral annulus • Does not inhibit LV function or obstruct LVOT • Preserves native structures in LV (chordae, papillary
Slide 14: Tiara Development Timeline
Tiara Development Timeline • Multiple patent applications filed • Refined valves & transapical delivery systems developed • Preclinical testing underway (bench, acute / chronic animal) • Durability (accelerated wear) testing underway • Clinical technique developed & refined through multiple animal i
Slide 15: Tiara Market Opportunity
Tiara Market Opportunity • Success of transcatheter aortic valves has positioned transcatheter mitral valve replacement as major area of industry/clinical interest • 600,000 new patients per year with MR in US & EU • Only 20% of diagnosed patients currently undergo surgery • Minimally invasive mitra
Slide 16: Clinical Opinion Leaders
Clinical Opinion Leaders Leaders in interventional cardiology are assisting Neovasc programs • Dr. Shmuel Banai (Tel Aviv Medical Center) • Dr. Elazer Edelman (Harvard – MIT, Cambridge) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Marc Jolicoeur (Montreal Heart Institute) • Dr. Martin Leon (C
Slide 17: Neovasc Looking Forward
Neovasc Looking Forward Continued growth of tissue business • Steady growth in 2013 • Upside potential as customers’ products commercialize in 2014 forward Complete COSIRA trial for Reducer & pilot launch in Europe • Complete COSIRA enrollment in Apr/May 2013 • Release full efficacy data after 6-mon
Slide 18: Neovasc Recap
Neovasc Recap Product leader in 3 separate fields • Neovasc Tissue – Growing revenues & significant strategic value • Neovasc Reducer – CE marked & efficacy data in 2013 • Neovasc Tiara – Successful acute animal studies & rapid advance to clinical stage in 2013 Corporate Summary • Clean corporate st
Slide 19: Thank you
Thank you Qyesc